Is Athira Pharma Stock a Good Investment?
Athira Pharma Investment Advice | ATHA |
- Examine Athira Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Athira Pharma's leadership team and their track record. Good management can help Athira Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Athira Pharma's business and its evolving consumer preferences.
- Compare Athira Pharma's performance and market position to its competitors. Analyze how Athira Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Athira Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Athira Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Athira Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Athira Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Athira Pharma Stock
Researching Athira Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 52.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.3. Some equities with similar Price to Book (P/B) outperform the market in the long run. Athira Pharma recorded a loss per share of 2.52. The entity had not issued any dividends in recent years.
To determine if Athira Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Athira Pharma's research are outlined below:
| Athira Pharma generated a negative expected return over the last 90 days | |
| Athira Pharma has some characteristics of a very speculative penny stock | |
| Athira Pharma has high historical volatility and very poor performance | |
| Athira Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (96.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Athira Pharma currently holds about 252.4 M in cash with (97.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Disposition of 2525 shares by Kevin Church of Athira Pharma at 0.566 subject to Rule 16b-3 |
Athira Pharma Quarterly Cost Of Revenue |
|
Athira Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Athira Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Athira Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Athira Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Athira Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Athira Pharma backward and forwards among themselves. Athira Pharma's institutional investor refers to the entity that pools money to purchase Athira Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 320.8 K | Gsa Capital Partners Llp | 2024-12-31 | 296.6 K | Two Sigma Advisers, Llc | 2024-12-31 | 253.3 K | Renaissance Technologies Corp | 2024-12-31 | 207.3 K | Royal Bank Of Canada | 2024-12-31 | 183 K | Laird Norton Tyee Trust Co | 2024-12-31 | 127.3 K | State Street Corp | 2024-12-31 | 107.4 K | Ubs Group Ag | 2024-12-31 | 87 K | Advisor Group Holdings, Inc. | 2024-12-31 | 81.3 K | Perceptive Advisors Llc | 2024-12-31 | 5.4 M | Bml Capital Management Llc | 2024-12-31 | 2.8 M |
Athira Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.84 M.Market Cap |
|
Athira Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.65) | (1.57) | |
| Return On Capital Employed | (2.21) | (2.32) | |
| Return On Assets | (1.65) | (1.57) | |
| Return On Equity | (2.16) | (2.05) |
Determining Athira Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Athira Pharma is a good buy. For example, gross profit margin measures Athira Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Athira Pharma's profitability and make more informed investment decisions.
Please note, the presentation of Athira Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Athira Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Athira Pharma's management manipulating its earnings.
Evaluate Athira Pharma's management efficiency
Athira Pharma has return on total asset (ROA) of (0.5523) % which means that it has lost $0.5523 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1077) %, meaning that it created substantial loss on money invested by shareholders. Athira Pharma's management efficiency ratios could be used to measure how well Athira Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.57. In addition to that, Return On Capital Employed is expected to decline to -2.32. The current year's Other Current Assets is expected to grow to about 4.2 M, whereas Total Assets are forecasted to decline to about 55.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.17 | 1.22 | |
| Tangible Book Value Per Share | 1.17 | 1.22 | |
| Enterprise Value Over EBITDA | 0.24 | 0.26 | |
| Price Book Value Ratio | 0.50 | 0.53 | |
| Enterprise Value Multiple | 0.24 | 0.26 | |
| Price Fair Value | 0.50 | 0.53 | |
| Enterprise Value | -24.6 M | -23.4 M |
Examining the leadership quality of Athira Pharma offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 3.009 |
Basic technical analysis of Athira Stock
As of the 22nd of March, Athira Pharma shows the mean deviation of 3.6, and Risk Adjusted Performance of (0.13). Athira Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Athira Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Athira Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Athira Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Athira Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Athira Pharma's Outstanding Corporate Bonds
Athira Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Athira Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Athira bonds can be classified according to their maturity, which is the date when Athira Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Athira Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Athira Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | 3.73 | |||
| Mean Deviation | 3.6 | |||
| Coefficient Of Variation | (658.27) | |||
| Standard Deviation | 4.65 | |||
| Variance | 21.61 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.73) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | 3.72 | |||
| Maximum Drawdown | 21.64 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 6.45 | |||
| Skewness | 0.0748 | |||
| Kurtosis | 0.2903 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | 3.73 | |||
| Mean Deviation | 3.6 | |||
| Coefficient Of Variation | (658.27) | |||
| Standard Deviation | 4.65 | |||
| Variance | 21.61 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.73) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | 3.72 | |||
| Maximum Drawdown | 21.64 | |||
| Value At Risk | (8.33) | |||
| Potential Upside | 6.45 | |||
| Skewness | 0.0748 | |||
| Kurtosis | 0.2903 |
Consider Athira Pharma's intraday indicators
Athira Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Athira Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Athira Pharma time-series forecasting models is one of many Athira Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Athira Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Athira Stock media impact
Far too much social signal, news, headlines, and media speculation about Athira Pharma that are available to investors today. That information is available publicly through Athira media outlets and privately through word of mouth or via Athira internal channels. However, regardless of the origin, that massive amount of Athira data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Athira Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Athira Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Athira Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Athira Pharma alpha.
Athira Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Athira Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Athira Pharma Corporate Management
| Mark JD | General Secretary | Profile | |
| Samantha Willing | Executive People | Profile | |
| Robert Renninger | Director Reporting | Profile | |
| Kevin Church | Chief Officer | Profile | |
| Javier MD | Chief Officer | Profile | |
| MBA MBA | CEO Pres | Profile |
Already Invested in Athira Pharma?
The danger of trading Athira Pharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Athira Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Athira Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Athira Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Athira Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.